{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:50:41Z","timestamp":1772121041880,"version":"3.50.1"},"reference-count":138,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jceh.2017.11.012","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T12:10:13Z","timestamp":1512735013000},"page":"81-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?"],"prefix":"10.1016","volume":"8","author":[{"given":"Chalermrat","family":"Bunchorntavakul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Mitrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2017.11.012_bib0695","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.dld.2006.06.008","article-title":"Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach","volume":"39","author":"Zignego","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib0700","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0168-8278(92)90073-X","article-title":"Infection of peripheral mononuclear blood cells by hepatitis C virus","volume":"15","author":"Zignego","year":"1992","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0705","doi-asserted-by":"crossref","first-page":"9213","DOI":"10.1128\/JVI.73.11.9213-9221.1999","article-title":"Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets","volume":"73","author":"Roque Afonso","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0710","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1099-1654(200003\/04)10:2<101::AID-RMV268>3.0.CO;2-W","article-title":"The role of the hepatitis C virus glycoproteins in infection","volume":"10","author":"Flint","year":"2000","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0715","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood.V98.13.3745","article-title":"The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis","volume":"98","author":"Quinn","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib0720","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clim.2010.02.002","article-title":"Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients","volume":"135","author":"Ito","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0725","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/blood.V91.7.2433","article-title":"Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1\/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas","volume":"91","author":"Ivanovski","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib0730","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1128\/JVI.79.13.8079-8089.2005","article-title":"Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells","volume":"79","author":"Machida","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0735","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1128\/JVI.00321-06","article-title":"Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation","volume":"80","author":"Machida","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0740","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cld.2008.03.012","article-title":"Extrahepatic manifestations of hepatitis C virus infection","volume":"12","author":"Zignego","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib0745","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1073\/pnas.0303971101","article-title":"Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes","volume":"101","author":"Machida","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jceh.2017.11.012_bib0750","doi-asserted-by":"crossref","first-page":"8835","DOI":"10.1128\/JVI.78.16.8835-8843.2004","article-title":"Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes","volume":"78","author":"Machida","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0755","doi-asserted-by":"crossref","first-page":"16197","DOI":"10.3748\/wjg.v20.i43.16197","article-title":"Hepatitis C infection and lymphoproliferative disease: accidental comorbidities?","volume":"20","author":"Khoury","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0760","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","article-title":"Bcl-2-family proteins and hematologic malignancies: history and future prospects","volume":"111","author":"Reed","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib0765","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0770","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood.V96.8.2910","article-title":"Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II","volume":"96","author":"Kitay-Cohen","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib0775","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.510310230","article-title":"T(14;18) translocation in chronic hepatitis C virus infection","volume":"31","author":"Zignego","year":"2000","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jceh.2017.11.012_bib0780","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7326\/0003-4819-137-7-200210010-00008","article-title":"Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas","volume":"137","author":"Zignego","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib0785","first-page":"165","article-title":"Frequency of bcl-2\/IgH translocation in patients with non-Hodgkin's lymphoma and chronic hepatitis C virus infection","volume":"51","author":"Libra","year":"2005","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0790","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2008.03.031","article-title":"Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas","volume":"49","author":"Libra","year":"2008","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2017.11.012_bib0795","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1590-8658(07)80005-3","article-title":"HCV-related autoimmune and neoplastic disorders: the HCV syndrome","volume":"39","author":"Ferri","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib0800","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3748\/wjg.v13.i17.2467","article-title":"Hepatitis C virus-related lymphoproliferative disorders: an overview","volume":"13","author":"Zignego","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0805","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2249.2000.01396.x","article-title":"Hepatitis C virus (HCV) in lymphocyte subsets and in B lymphocytes expressing rheumatoid factor cross-reacting idiotype in type II mixed cryoglobulinaemia","volume":"122","author":"Fornasieri","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0810","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0168-8278(02)00353-7","article-title":"Enhanced monocyte Th1 cytokine production in HCV-infected cryoglobulinemic patients","volume":"38","author":"Loffreda","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0815","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2004.08.011","article-title":"Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis","volume":"41","author":"Saadoun","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0820","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2003-07-2598","article-title":"CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis","volume":"103","author":"Boyer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib0825","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib0830","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/07853899908995902","article-title":"Mixed cryoglobulinaemia in patients with chronic hepatitis C infection: prevalence, significance and relationship with different viral genotypes","volume":"31","author":"Horcajada","year":"1999","journal-title":"Ann Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib0835","first-page":"643","article-title":"Cryoglobulinemia in chronic hepatitis C virus infection: prevalence, clinical manifestations, response to interferon treatment and analysis of cryoprecipitates","volume":"33","author":"Hartmann","year":"1995","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0840","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1074\/jbc.M311470200","article-title":"Fcgamma receptor-like activity of hepatitis C virus core protein","volume":"279","author":"Maillard","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jceh.2017.11.012_bib0845","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1473-3099(05)70053-0","article-title":"Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations","volume":"5","author":"Sansonno","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib0850","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0002-9343(74)90852-3","article-title":"Biologic and clinical significance of cryoglobulins. A report of 86 cases","volume":"57","author":"Brouet","year":"1974","journal-title":"Am J Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib0855","first-page":"115","article-title":"Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias","volume":"88","author":"Monti","year":"1995","journal-title":"QJM"},{"key":"10.1016\/j.jceh.2017.11.012_bib0860","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","article-title":"A role for hepatitis C virus infection in type II cryoglobulinemia","volume":"327","author":"Agnello","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib0865","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib0870","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-122-3-199502010-00002","article-title":"Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes","volume":"122","author":"Pawlotsky","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib0875","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0168-8278(96)80200-5","article-title":"Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia","volume":"25","author":"Frangeul","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0880","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jinf.2004.05.002","article-title":"Cryoglobulinemia and progression of fibrosis in chronic HCV infection: cause or effect?","volume":"49","author":"Siagris","year":"2004","journal-title":"J Infect"},{"key":"10.1016\/j.jceh.2017.11.012_bib0885","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/0016-5085(94)90022-1","article-title":"Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage","volume":"106","author":"Lunel","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2017.11.012_bib0890","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","article-title":"Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C","volume":"42","author":"Cacoub","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib0895","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2893.2000.00204.x","article-title":"Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C","volume":"7","author":"Cicardi","year":"2000","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jceh.2017.11.012_bib0900","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2249.1996.d01-639.x","article-title":"Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection","volume":"104","author":"Wong","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0905","first-page":"2199","article-title":"Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus","volume":"31","author":"Sene","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0910","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2017.11.012_bib0915","article-title":"The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection","author":"Mahale","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2017.11.012_bib0920","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/jhep.2002.35620","article-title":"Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis","volume":"36","author":"Kayali","year":"2002","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jceh.2017.11.012_bib0925","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.297.18.2010","article-title":"Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus","volume":"297","author":"Giordano","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jceh.2017.11.012_bib0930","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/jcp.55.1.4","article-title":"Cryoglobulins","volume":"55","author":"Ferri","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0935","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ki.2009.247","article-title":"Hepatitis C virus-induced cryoglobulinemia","volume":"76","author":"Charles","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jceh.2017.11.012_bib0940","first-page":"1338","article-title":"HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders","volume":"24","author":"Congia","year":"1996","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jceh.2017.11.012_bib0945","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0168-8278(98)80176-1","article-title":"Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglobulinemia type II after hepatitis C virus infection?","volume":"29","author":"Amoroso","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0950","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood.V91.6.2062","article-title":"Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia","volume":"91","author":"Lenzi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib0955","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmv.2000","article-title":"Cryoglobulinemia in Japanese patients with chronic hepatitis C virus infection: host genetic and virological study","volume":"65","author":"Nagasaka","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0960","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1034\/j.1399-0039.2002.590106.x","article-title":"Genetic predispositions for the presence of cryoglobulinemia and serum autoantibodies in Chinese patients with chronic hepatitis C","volume":"59","author":"Hwang","year":"2002","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jceh.2017.11.012_bib0965","first-page":"17","article-title":"Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients","volume":"19","author":"Sebastiani","year":"2005","journal-title":"J Biol Regul Homeost Agents"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2017.11.012_bib0970","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S1590-8658(07)80014-4","article-title":"Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus","volume":"39","author":"De Re","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib0975","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/gene.2014.41","article-title":"Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis","volume":"15","author":"Zignego","year":"2014","journal-title":"Genes Immunity"},{"key":"10.1016\/j.jceh.2017.11.012_bib0980","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/art.30274","article-title":"Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors","volume":"63","author":"Gragnani","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib0985","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3899\/jrheum.090790","article-title":"Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy","volume":"37","author":"Landau","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib0990","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.md.0000157397.30055.c9","article-title":"Sjogren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases","volume":"84","author":"Ramos-Casals","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jceh.2017.11.012_bib0995","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib1000","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.autrev.2004.04.004","article-title":"Hepatitis C virus, Sjogren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer","volume":"4","author":"Ramos-Casals","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jceh.2017.11.012_bib1005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keh407","article-title":"Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome","volume":"44","author":"Ramos-Casals","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1010","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ki.1995.78","article-title":"Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis","volume":"47","author":"Tarantino","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.jceh.2017.11.012_bib1015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0002-9343(99)00014-5","article-title":"Renal manifestations of hepatitis C infection","volume":"106","author":"Daghestani","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib1020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.ajkd.2006.09.015","article-title":"Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis","volume":"49","author":"Roccatello","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib1025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ki.1994.393","article-title":"Renal manifestations of hepatitis C virus infection","volume":"46","author":"Johnson","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.jceh.2017.11.012_bib1030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00005792-200209000-00005","article-title":"The clinical and morphologic spectrum of renal cryoglobulinemia","volume":"81","author":"Beddhu","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1035","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/hep.21190","article-title":"Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C","volume":"43","author":"Saadoun","year":"2006","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1040","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1053\/j.gastro.2003.09.025","article-title":"Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis","volume":"125","author":"Gisbert","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2017.11.012_bib1045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.165.1.101","article-title":"Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias","volume":"165","author":"Monti","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib1050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1258\/acb.2009.009180","article-title":"Cryoglobulin evaluation: best practice?","volume":"47","author":"Sargur","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.jceh.2017.11.012_bib1055","first-page":"395","article-title":"Cryoglobulins: an important but neglected clinical test","volume":"36","author":"Shihabi","year":"2006","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.jceh.2017.11.012_bib1060","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1002\/art.20594","article-title":"Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection","volume":"50","author":"Vallat","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib1065","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/rheumatology\/kem209","article-title":"Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis","volume":"46","author":"Quartuccio","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1750-1172-3-25","article-title":"Mixed cryoglobulinemia","volume":"3","author":"Ferri","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib1075","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.amjmed.2009.09.038","article-title":"Management of hepatitis C virus-related mixed cryoglobulinemia","volume":"123","author":"Iannuzzella","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib1080","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/j.ajkd.2003.11.020","article-title":"Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN","volume":"43","author":"Alric","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib1085","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.20958","article-title":"PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis","volume":"52","author":"Cacoub","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib1090","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2004.10.031","article-title":"Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study","volume":"42","author":"Mazzaro","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1095","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study","volume":"54","author":"Saadoun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib1100","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/jmv.23562","article-title":"Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies","volume":"85","author":"Fabrizi","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1105","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1110","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib1115","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study","volume":"61","author":"Gragnani","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1120","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2604::AID-CNCR26>3.0.CO;2-V","article-title":"Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy","volume":"77","author":"Mazzaro","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.jceh.2017.11.012_bib1125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2017.11.012_bib1130","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","article-title":"Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience","volume":"23","author":"Vallisa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1135","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1140","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2017.11.012_bib1145","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study","volume":"75","author":"Saadoun","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib1150","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/rheumatology\/kew268","article-title":"Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy","volume":"55","author":"Sollima","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1155","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/1389450117666160208145432","article-title":"Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study","volume":"18","author":"Gragnani","year":"2017","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jceh.2017.11.012_bib1160","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jhep.2017.02.010","article-title":"Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection","volume":"66","author":"Ramos-Casals","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1165","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.02.037","article-title":"Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis","volume":"152","author":"Comarmond","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2017.11.012_bib1170","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2017.49","article-title":"Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia","author":"Emery","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","article-title":"PegIFNalpha\/ribavirin\/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis","volume":"62","author":"Saadoun","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1185","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","article-title":"Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals","volume":"15","author":"Bonacci","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1190","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood-2002-05-1537","article-title":"Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation","volume":"102","author":"Giannelli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib1195","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.20518","article-title":"Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"41","author":"Radkowski","year":"2005","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jceh.2017.11.012_bib1200","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2007-09-112490","article-title":"Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia","volume":"111","author":"Giannini","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib1205","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.23305","article-title":"Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response","volume":"58","author":"Landau","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib1210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13730-016-0244-z","article-title":"A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant","volume":"6","author":"Obata","year":"2017","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.jceh.2017.11.012_bib1215","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/hepr.12629","article-title":"Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: a case report","volume":"46","author":"Tsuge","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jceh.2017.11.012_bib1220","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jceh.2017.11.012_bib1225","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00535-016-1174-4","article-title":"Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis","volume":"51","author":"Toyoda","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1230","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jvh.12553","article-title":"Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study","volume":"23","author":"Kawakami","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jceh.2017.11.012_bib1235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jare.2016.07.005","article-title":"New insights into HCV-related rheumatologic disorders: a review","volume":"8","author":"Cacoub","year":"2017","journal-title":"J Adv Res"},{"key":"10.1016\/j.jceh.2017.11.012_bib1245","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib1250","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib1255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12016-007-8019-0","article-title":"Rituximab as a therapeutic tool in severe mixed cryoglobulinemia","volume":"34","author":"Roccatello","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1260","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood-2009-11-253948","article-title":"Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease","volume":"116","author":"Petrarca","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib1265","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib1270","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood-2006-08-041525","article-title":"Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease","volume":"109","author":"Lake-Bakaar","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib1275","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/art.24703","article-title":"Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients","volume":"60","author":"Terrier","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib1280","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1285","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2007.081653","article-title":"Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis","volume":"67","author":"Saadoun","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jceh.2017.11.012_bib1290","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jceh.2017.11.012_bib1295","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1002\/art.25000","article-title":"Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis","volume":"60","author":"Sene","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib1300","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/1529-0131(199912)42:12<2507::AID-ANR2>3.0.CO;2-#","article-title":"Cryoglobulinemic vasculitis","volume":"42","author":"Lamprecht","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jceh.2017.11.012_bib1305","first-page":"813","article-title":"Therapy of hepatitis C virus-associated glomerulonephritis: current approaches","volume":"21","author":"Fabrizi","year":"2008","journal-title":"J Nephrol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1310","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0192-0561(99)00005-3","article-title":"Effects of corticosteroids on HCV infection","volume":"21","author":"Magy","year":"1999","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1315","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1196\/annals.1423.046","article-title":"Impact of steroids on hepatitis C virus replication in vivo and in vitro","volume":"1110","author":"Henry","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jceh.2017.11.012_bib1320","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2008.01039.x","article-title":"Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C","volume":"80","author":"Dizdar","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1325","first-page":"S115","article-title":"How HCV has changed the approach to mixed cryoglobulinemia","volume":"27","author":"Della Rossa","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1330","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1665-2681(19)31928-3","article-title":"Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis","volume":"6","author":"Saleh","year":"2007","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1335","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3748\/wjg.15.2290","article-title":"Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer","volume":"15","author":"Ceballos-Viro","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1340","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/039139880703000306","article-title":"Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials","volume":"30","author":"Fabrizi","year":"2007","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.jceh.2017.11.012_bib1345","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00296-004-0577-3","article-title":"Severe, refractory type II essential mixed cryoglobulinemia treated with 2-chlorodeoxyadenosine and mycophenolate mofetil","volume":"25","author":"Gladstone","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jceh.2017.11.012_bib1350","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/keh080","article-title":"Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia","volume":"43","author":"Chandesris","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl 13","key":"10.1016\/j.jceh.2017.11.012_bib1355","first-page":"S201","article-title":"A pilot study on the effectiveness of cyclosporine in type II mixed cryoglobulinemia","volume":"13","author":"Ballare","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1360","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.transci.2010.03.001","article-title":"Plasma exchange for treating cryoglobulinemia: a descriptive analysis","volume":"42","author":"Rockx","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jceh.2017.11.012_bib1365","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/jca.20166","article-title":"Double-filtration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia","volume":"23","author":"Ramunni","year":"2008","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jceh.2017.11.012_bib1370","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jca.20222","article-title":"Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia","volume":"24","author":"Stefanutti","year":"2009","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jceh.2017.11.012_bib1375","first-page":"2977A","article-title":"Treatment of cryoglobulinemic vasculitis with sofosbuvir in four combination protocols","volume":"68","author":"Hegazy","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jceh.2017.11.012_bib1380","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.autrev.2011.04.033","article-title":"A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection","volume":"10","author":"Visentini","year":"2011","journal-title":"Autoimmun Rev"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688317305029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688317305029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:04:23Z","timestamp":1760853863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688317305029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0973688317305029"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2017.11.012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735479288.793558614","asserted-by":"object"}]},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2017.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 INASL.","name":"copyright","label":"Copyright"}]}}